Insider Trading activities of Gilead Sciences Inc insiders. , Part 9

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Gilead Sciences Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Gilead Sciences Inc since year 2005. (See page 1 of this report.) Table 2 shows the detailed insider transactions of Gilead Sciences Inc since 2005. The reporting company's ticker symbol is GILD. The reporting company's CIK number is 882095.
The total value of stock buying since 2005 is $2,912,783.
The total value of stock sales since 2005 is $2,341,165,981.
The total value of stock option exercises since 2005 is $444,271,390.



Table 2. Detailed insider stock purchases, sales, and option exercises of Gilead Sciences Inc insiders (GILD) , Part 9
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2007-05-01 Berg Paul Option Ex 3,750 5.41 20,272
2007-04-30 Berg Paul Sale 3,750 81.36 305,085
2007-04-30 Berg Paul Option Ex 3,750 5.41 20,272
2007-04-25 Toole John J (SVP, Clinical Research) Sale 19,148 83.09 1,591,103
2007-04-25 Toole John J (SVP, Clinical Research) Option Ex 19,148 13.60 260,451
2007-04-24 Meyers James R (SVP Comm Ops North America) Sale 9,000 83.17 748,557
2007-04-24 Meyers James R (SVP Comm Ops North America) Option Ex 9,000 7.40 66,582
2007-04-24 Hills Carla A Buy 121 83.20 10,067
2007-04-23 Lee William A (SVP, Research) Sale 92,796 83.04 7,708,750
2007-04-23 Lee William A (SVP, Research) Option Ex 92,796 10.78 1,000,619
2007-04-19 Alton Gregg H (SVP, General Counsel) Sale 14,500 80.00 1,160,000
2007-04-19 Alton Gregg H (SVP, General Counsel) Option Ex 14,500 17.16 248,849
2007-04-10 Martin John C (President and CEO) Sale 35,000 78.14 2,734,970
2007-04-10 Martin John C (President and CEO) Option Ex 35,000 2.86 100,065
2007-04-02 Alton Gregg H (SVP, General Counsel) Sale 4,750 76.42 362,971
2007-04-02 Alton Gregg H (SVP, General Counsel) Option Ex 4,750 17.16 81,519
2007-03-23 Alton Gregg H (SVP, General Counsel) Sale 30,200 75.00 2,265,000
2007-03-23 Alton Gregg H (SVP, General Counsel) Option Ex 20,200 15.38 310,716
2007-03-14 Berg Paul Sale 6,500 68.83 447,401
2007-03-14 Berg Paul Option Ex 6,500 4.78 31,076
2007-03-13 Martin John C (President and CEO) Sale 35,000 70.26 2,458,960
2007-03-13 Martin John C (President and CEO) Option Ex 35,000 2.86 100,065
2007-03-06 Denny James M Sale 30,000 70.62 2,116,514
2007-03-06 Denny James M Option Ex 40,000 5.68 227,079
2007-03-01 Alton Gregg H (SVP, General Counsel) Sale 4,750 70.21 333,497
2007-03-01 Alton Gregg H (SVP, General Counsel) Option Ex 4,750 13.60 64,609
2007-02-28 Meyers James R (SVP Comm Ops North America) Sale 6,000 71.35 428,088
2007-02-28 Meyers James R (SVP Comm Ops North America) Option Ex 6,000 8.21 49,266
2007-02-23 Toole John J (SVP, Clinical Research) Sale 20,000 73.27 1,465,420
2007-02-23 Toole John J (SVP, Clinical Research) Option Ex 20,000 13.60 272,040
2007-02-22 Milligan John F (EVP, Chief Financial Officer) Sale 20,000 73.63 1,472,620
2007-02-22 Milligan John F (EVP, Chief Financial Officer) Option Ex 20,000 8.60 172,079
2007-02-21 Yang Taiyin (SVP, Pharm Dev & Mfg) Sale 20,000 73.74 1,474,820
2007-02-21 Moore Gordon Earle Option Ex 16,000 3.28 52,496
2007-02-20 Young Kevin (EVP, Commercial Operations) Sale 30,000 72.30 2,168,880
2007-02-20 Young Kevin (EVP, Commercial Operations) Option Ex 30,000 33.69 1,010,550
2007-02-16 Lee William A (SVP, Research) Sale 32,000 72.00 2,303,840
2007-02-16 Lee William A (SVP, Research) Option Ex 32,000 7.41 236,992
2007-02-15 Lee William A (SVP, Research) Sale 20,000 72.03 1,440,660
2007-02-15 Lee William A (SVP, Research) Option Ex 20,000 7.41 148,120
2007-02-13 Martin John C (President and CEO) Sale 35,000 70.88 2,480,940
2007-02-13 Martin John C (President and CEO) Option Ex 35,000 2.86 100,065
2007-02-09 Bischofberger Norbert W (EVP, Research) Sale 133,920 71.27 9,544,478
2007-02-09 Bischofberger Norbert W (EVP, Research) Option Ex 140,000 16.44 2,301,180
2007-02-06 Yang Taiyin (SVP, Pharm Dev & Mfg) Sale 20,000 70.23 1,404,600
2007-02-06 Davignon Etienne Sale 19,000 69.95 1,329,068
2007-02-01 Alton Gregg H (SVP, General Counsel) Sale 20,650 70.38 1,453,243
2007-02-01 Alton Gregg H (SVP, General Counsel) Option Ex 20,650 13.60 280,881
2007-01-10 Berg Paul Sale 6,500 64.42 418,704
2007-01-10 Berg Paul Option Ex 6,500 4.78 31,076
2007-01-09 Martin John C (President and CEO) Sale 35,000 65.34 2,286,865
2007-01-09 Martin John C (President and CEO) Option Ex 35,000 2.86 100,065
2007-01-03 Alton Gregg H (SVP, General Counsel) Sale 3,550 64.49 228,950
2007-01-03 Alton Gregg H (SVP, General Counsel) Option Ex 3,550 13.60 48,287
2006-12-20 Toole John J (SVP, Clinical Research) Option Ex 4,000 7.40 29,592
2006-12-20 Milligan John F (EVP, Chief Financial Officer) Option Ex 4,060 7.08 28,736
2006-12-12 Martin John C (President and CEO) Sale 35,000 65.51 2,292,745
2006-12-12 Martin John C (President and CEO) Option Ex 35,000 2.86 100,065
2006-12-04 Alton Gregg H (SVP, General Counsel) Sale 1,200 67.00 80,400
2006-12-04 Alton Gregg H (SVP, General Counsel) Option Ex 1,200 13.60 16,322
2006-12-01 Alton Gregg H (SVP, General Counsel) Sale 3,550 65.12 231,176
2006-12-01 Alton Gregg H (SVP, General Counsel) Option Ex 3,550 13.60 48,287
2006-11-22 Lee William A (SVP, Research) Option Ex 20,000 3.27 65,300
2006-11-20 Alton Gregg H (SVP, General Counsel) Sale 100 70.00 7,000
2006-11-20 Alton Gregg H (SVP, General Counsel) Option Ex 100 13.60 1,360
2006-11-17 Toole John J (SVP, Clinical Research) Sale 36,328 68.96 2,505,287
2006-11-17 Toole John J (SVP, Clinical Research) Option Ex 36,528 10.30 376,347
2006-11-17 Moore Nicholas G Sale 30,020 68.42 2,059,687
2006-11-17 Moore Nicholas G Option Ex 30,000 26.73 801,900
2006-11-14 Martin John C (President and CEO) Sale 35,000 66.66 2,333,240
2006-11-14 Martin John C (President and CEO) Option Ex 35,000 2.86 100,065
2006-11-08 Berg Paul Sale 6,500 69.41 451,178
2006-11-08 Berg Paul Option Ex 6,500 4.78 31,076
2006-11-08 Denny James M Sale 30,000 68.72 2,061,569
2006-11-08 Denny James M Option Ex 40,000 5.13 205,280
2006-11-01 Alton Gregg H (SVP, General Counsel) Sale 4,750 68.28 323,978
2006-11-01 Alton Gregg H (SVP, General Counsel) Option Ex 4,750 13.60 64,609
2006-10-30 Milligan John F (EVP, Chief Financial Officer) Sale 30,000 68.71 2,061,389
2006-10-30 Milligan John F (EVP, Chief Financial Officer) Option Ex 30,000 7.40 221,940
2006-10-27 Davignon Etienne Option Ex 40,000 3.12 125,000
2006-10-26 Lee William A (SVP, Research) Sale 61,000 69.11 4,215,954
2006-10-26 Lee William A (SVP, Research) Option Ex 61,000 7.40 451,278
2006-10-25 Bischofberger Norbert W (EVP, Research) Sale 140,000 67.73 9,501,879
2006-10-25 Bischofberger Norbert W (EVP, Research) Option Ex 140,000 17.89 2,503,900
2006-10-24 Davignon Etienne Sale 2,000 68.82 137,632
2006-10-24 Lee William A (SVP, Research) Sale 23,000 69.25 1,592,750
2006-10-24 Lee William A (SVP, Research) Option Ex 23,000 7.40 170,154
2006-10-23 Lee William A (SVP, Research) Sale 30,000 69.37 2,081,190
2006-10-23 Lee William A (SVP, Research) Option Ex 30,000 7.40 221,940
2006-10-19 Moore Gordon Earle Option Ex 56,000 3.12 175,000
2006-10-12 Alton Gregg H (SVP, General Counsel) Sale 1,200 67.00 80,400
2006-10-12 Alton Gregg H (SVP, General Counsel) Option Ex 1,200 13.60 16,322
2006-10-10 Martin John C (President and CEO) Sale 35,000 64.50 2,257,640
2006-10-10 Martin John C (President and CEO) Option Ex 35,000 2.86 100,065
2006-10-02 Alton Gregg H (SVP, General Counsel) Sale 3,550 64.96 230,597
2006-10-02 Alton Gregg H (SVP, General Counsel) Option Ex 3,550 13.60 48,287
2006-09-27 Alton Gregg H (SVP, General Counsel) Sale 2,400 67.00 160,800
2006-09-27 Alton Gregg H (SVP, General Counsel) Option Ex 1,112 13.60 15,125
2006-09-13 Berg Paul Sale 6,500 63.45 412,392
2006-09-13 Berg Paul Option Ex 6,500 4.78 31,076
2006-09-12 Martin John C (President and CEO) Sale 35,000 62.85 2,199,610
2006-09-12 Martin John C (President and CEO) Option Ex 35,000 2.86 100,065
2006-09-01 Alton Gregg H (SVP, General Counsel) Sale 3,550 63.56 225,638
2006-08-17 Alton Gregg H (SVP, General Counsel) Sale 3,550 64.25 228,080
2006-08-16 Toole John J (SVP, Clinical Research) Sale 51,432 63.74 3,278,332
2006-08-16 Toole John J (SVP, Clinical Research) Option Ex 50,000 8.60 430,199
2006-08-09 Young Kevin (EVP, Commercial Operations) Sale 24,000 62.03 1,488,720
2006-08-09 Young Kevin (EVP, Commercial Operations) Option Ex 24,000 32.02 768,480
2006-08-09 Lee William A (SVP, Research) Sale 53,896 62.58 3,372,811
2006-08-09 Lee William A (SVP, Research) Option Ex 53,896 7.30 393,225
2006-08-09 Denny James M Sale 60,000 62.05 3,725,544
2006-08-09 Denny James M Option Ex 80,000 4.96 396,560
2006-08-08 Lee William A (SVP, Research) Sale 30,000 61.91 1,857,300
2006-08-08 Lee William A (SVP, Research) Option Ex 30,000 7.30 218,880
2006-08-01 Martin John C (President and CEO) Sale 120,000 60.57 7,268,520
2006-08-01 Martin John C (President and CEO) Option Ex 120,000 3.06 367,440
2006-08-01 Bischofberger Norbert W (EVP, Research) Sale 120,000 60.51 7,260,840
2006-08-01 Bischofberger Norbert W (EVP, Research) Option Ex 120,000 16.44 1,972,440
2006-07-25 Alton Gregg H (SVP, General Counsel) Sale 5,000 62.00 310,000
2006-07-25 Milligan John F (EVP, Chief Financial Officer) Sale 60,000 60.84 3,650,100
2006-07-25 Milligan John F (EVP, Chief Financial Officer) Option Ex 60,000 9.58 574,680
2006-07-12 Berg Paul Sale 6,500 61.66 400,261
2006-07-12 Berg Paul Option Ex 6,500 4.78 31,076
2006-06-23 Alton Gregg H (SVP, General Counsel) Option Ex 2,788 11.44 31,883
2006-05-18 Martin John C (President and CEO) Option Ex 39,936 2.86 114,176
2006-05-17 Bischofberger Norbert W (EVP, Research) Sale 100,000 55.64 5,563,900
2006-05-17 Bischofberger Norbert W (EVP, Research) Option Ex 100,000 16.44 1,643,700
2006-05-15 Martin John C (President and CEO) Sale 120,000 57.05 6,846,000
2006-05-15 Martin John C (President and CEO) Option Ex 120,000 3.27 391,800
2006-05-10 Berg Paul Sale 6,500 57.27 372,268
2006-05-10 Berg Paul Option Ex 6,500 4.78 31,076
2006-05-10 Denny James M Sale 30,000 57.65 1,729,440
2006-05-10 Denny James M Option Ex 40,000 4.78 191,240
2006-04-28 Lee William A (SVP, Research) Option Ex 10,000 3.27 32,650
2006-03-08 Berg Paul Sale 6,500 59.18 384,676
2006-03-08 Berg Paul Option Ex 6,500 4.78 31,076
2006-03-06 Alton Gregg H (SVP, General Counsel) Option Ex 14,894 9.42 140,286
2006-03-06 Denny James M Sale 30,000 59.75 1,792,560
2006-03-06 Denny James M Option Ex 40,000 3.95 158,120
2006-02-22 Yang Taiyin (SVP, Pharm Dev & Mfg) Sale 20,000 61.20 1,223,920
2006-02-16 Martin John C (President and CEO) Sale 120,000 61.73 7,407,840
2006-02-16 Martin John C (President and CEO) Option Ex 120,000 3.27 391,800
2006-02-15 Lee William A (SVP, Research) Sale 20,000 60.88 1,217,500
2006-02-14 Lee William A (SVP, Research) Sale 30,000 60.25 1,807,500
2006-02-14 Bischofberger Norbert W (EVP, Research) Sale 136,488 59.13 8,070,262
2006-02-14 Bischofberger Norbert W (EVP, Research) Option Ex 136,488 11.92 1,626,663
2006-02-13 Yang Taiyin (SVP, Pharm Dev & Mfg) Option Ex 99,046 8.38 830,500
2006-02-13 Bischofberger Norbert W (EVP, Research) Option Ex 13,512 7.40 99,961
2006-02-09 Toole John J (SVP, Clinical Research) Sale 35,472 59.42 2,107,639
2006-02-09 Toole John J (SVP, Clinical Research) Option Ex 35,472 10.55 374,229
2006-02-08 Lee William A (SVP Research and PPD) Sale 10,000 60.50 605,000
2006-02-07 Lee William A (SVP Research and PPD) Sale 40,000 60.21 2,408,400
2006-02-07 Lee William A (SVP Research and PPD) Option Ex 10,000 7.30 72,970
2006-02-06 Milligan John F (EVP, Chief Financial) Sale 30,000 60.57 1,817,040
2006-02-06 Milligan John F (EVP, Chief Financial) Option Ex 30,000 11.76 352,740
2006-02-03 Young Kevin (EVP, Commercial Oper) Sale 25,000 61.21 1,530,350
2006-02-03 Young Kevin (EVP, Commercial Oper) Option Ex 25,000 33.69 842,125
2006-02-02 Alton Gregg H (SVP, General Counsel) Sale 10,000 60.24 602,450
2006-02-02 Young Kevin (EVP, Commercial Oper) Sale 50,000 60.41 3,020,600
2005-12-23 Toole John J (SVP, Clinical Resear) Option Ex 3,800 8.21 31,201
2005-12-23 Milligan John F (EVP, Chief Financial) Option Ex 5,500 7.19 39,534
2005-11-22 Yang Taiyin (Mfg) Sale 20,000 54.02 1,080,360
2005-11-22 Berg Paul Sale 6,000 54.50 327,000
2005-08-31 Yang Taiyin (Mfg) Sale 10,000 42.11 421,100
2005-05-27 Lee William A (SVP Research and PPD) Sale 20,000 41.08 821,500
2005-05-10 Caracciolo Anthony (SVP) Sale 5,518 38.85 214,390
2005-05-04 Shultz George P Sale 124,480 39.38 4,891,600

Insider trading activities including stock purchases, stock sales, and option exercises of GILD listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Gilead Sciences Inc (symbol GILD, CIK number 882095) see the Securities and Exchange Commission (SEC) website.